GE HealthCare Nihon Medi-Physics Acquisition Expands Presence in Japan and Molecular Imaging
GE HealthCare plans to acquire the remaining 50% stake in Nihon Medi-Physics from Sumitomo Chemical, giving it full ownership, subject to regulatory approvals.
NMP is a Japan-based radiopharmaceutical company focused on molecular imaging. It develops and manufactures products used in PET and SPECT scans for disease detection across neurology, cardiology and oncology. Its portfolio includes imaging agents used for Alzheimer’s disease, Parkinson’s disease and heart conditions.
Founded in 1973 and headquartered in Tokyo, NMP reported revenue of 28.2 billion JPY in 2023. It operates 13 manufacturing sites and invests in research across radiotracers and theranostics. GE HealthCare has held a 50% stake since 2004.
The acquisition is expected to strengthen GE HealthCare’s Pharmaceutical Diagnostics segment and expand its presence in Japan, one of the largest pharmaceutical markets. It also aims to support access to advanced radiopharmaceuticals and position NMP as a partner for global companies entering Japan and wider Asian markets.
Leave a comment